| Customization: | Available |
|---|---|
| CAS No.: | 154947-66-7 |
| Formula: | C205h340n60o53 |
|
Still deciding? Get samples of US$ 1700/G
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | LL-37 |
| Appearance | White powder |
| Purity | 99% |
| Storage | Keep in a cool, dry, dark location in a tightly sealed container or cylinder. |
| Shelf Life | 24 Months |
Description
The cathelicidin anti-microbial peptide LL-37 is involved in the reepithelialization of human skin wounds and is
lacking in chronic ulcer epithelium. LL-37(human) is a cathelicidin-derived peptide with antimicrobial and angiogenic
activity. Antimicrobial peptide derivative of human cathelicidin.
Antimicrobial peptide derivative of human cathelicidin. Induces FPRL1-mediated chemotaxis of human neutrophils,
monocytes and T cells in vitro. Promotes wound healing following skin-targeted electroporation of a plasmid encoding
hCAP-18/LL-37 in mice. Also triggers apoptosis in colon cancer cells.
Application&Function
LL-37 is the only known human Cathelicidin is a big protein family where the members exhibit diverse functions.
These peptides, essentially produced by macrophages and polymorphonuclear leukocytes (both types of white blood
cells), have bactericidal action. They have been found to have shown other substantial effects as well. The entire group
is often referred to as antimicrobial peptides (AMPs). LL-37 in particular has been found to play significant roles in
autoimmune disease, cancer, and wound healing.
1.Reduce apoptotic death of keratinocytes.
2.Improve IFN-alpha synthesis.
3.Suppress signaling through toll-like receptor 4 (TLR4).
4.Modify chemotaxis of neutrophils and eosinophils.
5.Trigger IL-18 production, and reduce levels of atherosclerotic plaques.
){kind=link}